RTx-015
/ Ray Therap
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
June 13, 2025
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
(clinicaltrials.gov)
- P1 | N=18 | Recruiting | Sponsor: Ray Therapeutics, Inc. | Trial completion date: May 2026 ➔ Oct 2030 | Trial primary completion date: May 2026 ➔ Oct 2030
Trial completion date • Trial primary completion date • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa
April 24, 2025
Ray Therapeutics Awarded $8M CIRM Grant to Advance RTx-015 Gene Therapy for Retinitis Pigmentosa
(Businesswire)
- "Ray Therapeutics...today announced it has been awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM). The grant will support the company’s ongoing clinical development of RTx-015 for the treatment of retinitis pigmentosa (RP), a progressive and debilitating inherited retinal disease that leads to blindness."
Financing • Retinitis Pigmentosa
August 23, 2024
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa Patients (ENVISION)
(clinicaltrials.gov)
- P1 | N=9 | Recruiting | Sponsor: Ray Therapeutics, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa
June 14, 2024
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa Patients
(clinicaltrials.gov)
- P1 | N=9 | Not yet recruiting | Sponsor: Ray Therapeutics, Inc.
New P1 trial • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa
1 to 4
Of
4
Go to page
1